Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.230
-0.140 (-3.20%)
At close: Jul 10, 2026, 4:00 PM EDT
4.250
+0.020 (0.47%)
After-hours: Jul 10, 2026, 7:57 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $71.43M in the quarter ending March 31, 2026, with 44.82% growth. This brings the company's revenue in the last twelve months to $285.61M, up 34.29% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth.
Revenue (ttm)
$285.61M
Revenue Growth
+34.29%
P/S Ratio
6.61
Revenue / Employee
$292,931
Employees
975
Market Cap
1.89B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.50M | 99.43M | 60.60% |
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UroGen Pharma | 140.49M |
| Zymeworks | 81.26M |
| Recursion Pharmaceuticals | 66.41M |
| Monte Rosa Therapeutics | 42.95M |
| Stoke Therapeutics | 32.08M |
| Precigen | 31.60M |
| Generate Biomedicines | 30.30M |
| AtaiBeckley | 3.49M |
IOVA News
- 11 days ago - Iovance Biotherapeutics Slides: Corporate presentation - Filings
- 22 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Iovance Biotherapeutics files automatic mixed securities shelf - TheFly
- 4 weeks ago - Iovance Biotherapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Iovance receives Australian approval of Amtagvi for advanced melanoma - TheFly
- 5 weeks ago - Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia - GlobeNewsWire
- 5 weeks ago - Iovance gets allowance to proceed from FDA for IOV-5001 IND application - TheFly